Hls Therapeutics Stock Performance
| HLS Stock | CAD 4.70 0.05 1.05% |
The company retains a Market Volatility (i.e., Beta) of -0.77, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HLS Therapeutics are expected to decrease at a much lower rate. During the bear market, HLS Therapeutics is likely to outperform the market. At this point, HLS Therapeutics has a negative expected return of -0.26%. Please make sure to check out HLS Therapeutics' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if HLS Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days HLS Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:5 | Dividend Date 2023-06-15 | Ex Dividend Date 2023-04-27 | Last Split Date 2006-10-26 |
1 | HLS Therapeutics to Announce Q3 2025 Financial Results - TipRanks | 10/30/2025 |
2 | Strategic Equity Report - news.stocktradersdaily.com | 11/14/2025 |
3 | Raymond James Sticks to Its Buy Rating for HLS Therapeutics Inc - The Globe and Mail | 11/19/2025 |
4 | Investment Report - news.stocktradersdaily.com | 12/19/2025 |
5 | HLS Therapeutics Stock Price Up 0.8 percent - Should You Buy - MarketBeat | 01/06/2026 |
| Begin Period Cash Flow | 22 M | |
| Total Cashflows From Investing Activities | 11.7 M |
HLS |
HLS Therapeutics Relative Risk vs. Return Landscape
If you would invest 555.00 in HLS Therapeutics on October 30, 2025 and sell it today you would lose (85.00) from holding HLS Therapeutics or give up 15.32% of portfolio value over 90 days. HLS Therapeutics is producing return of less than zero assuming 1.5684% volatility of returns over the 90 days investment horizon. Simply put, 14% of all stocks have less volatile historical return distribution than HLS Therapeutics, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
HLS Therapeutics Target Price Odds to finish over Current Price
The tendency of HLS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.70 | 90 days | 4.70 | about 84.13 |
Based on a normal probability distribution, the odds of HLS Therapeutics to move above the current price in 90 days from now is about 84.13 (This HLS Therapeutics probability density function shows the probability of HLS Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon HLS Therapeutics has a beta of -0.77. This usually indicates as returns on the benchmark increase, returns on holding HLS Therapeutics are expected to decrease at a much lower rate. During a bear market, however, HLS Therapeutics is likely to outperform the market. Additionally HLS Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. HLS Therapeutics Price Density |
| Price |
Predictive Modules for HLS Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as HLS Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.HLS Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. HLS Therapeutics is not an exception. The market had few large corrections towards the HLS Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold HLS Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of HLS Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.21 | |
β | Beta against Dow Jones | -0.77 | |
σ | Overall volatility | 0.28 | |
Ir | Information ratio | -0.21 |
HLS Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of HLS Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for HLS Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| HLS Therapeutics generated a negative expected return over the last 90 days | |
| HLS Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 56.62 M. Net Loss for the year was (19.66 M) with profit before overhead, payroll, taxes, and interest of 40.11 M. | |
| Latest headline from news.google.com: HLS Therapeutics Stock Price Up 0.8 percent - Should You Buy - MarketBeat |
HLS Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of HLS Stock often depends not only on the future outlook of the current and potential HLS Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. HLS Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 31.8 M | |
| Cash And Short Term Investments | 17.5 M |
HLS Therapeutics Fundamentals Growth
HLS Stock prices reflect investors' perceptions of the future prospects and financial health of HLS Therapeutics, and HLS Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HLS Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0186 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 206.34 M | ||||
| Shares Outstanding | 31.27 M | ||||
| Price To Book | 1.74 X | ||||
| Price To Sales | 2.64 X | ||||
| Revenue | 56.62 M | ||||
| Gross Profit | 40.11 M | ||||
| EBITDA | 17.22 M | ||||
| Net Income | (19.66 M) | ||||
| Cash And Equivalents | 20.72 M | ||||
| Cash Per Share | 1.70 X | ||||
| Total Debt | 66.45 M | ||||
| Debt To Equity | 50.50 % | ||||
| Current Ratio | 1.70 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | 8 M | ||||
| Earnings Per Share | (0.62) X | ||||
| Market Capitalization | 147.55 M | ||||
| Total Asset | 159.9 M | ||||
| Retained Earnings | (194.18 M) | ||||
| Working Capital | 12.86 M | ||||
About HLS Therapeutics Performance
By examining HLS Therapeutics' fundamental ratios, stakeholders can obtain critical insights into HLS Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that HLS Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 330.73 | 347.26 | |
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.14) | (0.13) | |
| Return On Equity | (0.32) | (0.30) |
Things to note about HLS Therapeutics performance evaluation
Checking the ongoing alerts about HLS Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HLS Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HLS Therapeutics generated a negative expected return over the last 90 days | |
| HLS Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 56.62 M. Net Loss for the year was (19.66 M) with profit before overhead, payroll, taxes, and interest of 40.11 M. | |
| Latest headline from news.google.com: HLS Therapeutics Stock Price Up 0.8 percent - Should You Buy - MarketBeat |
- Analyzing HLS Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HLS Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining HLS Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HLS Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HLS Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HLS Therapeutics' stock. These opinions can provide insight into HLS Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.